Company profile
Auxly Cannabis Group Inc.
OTC: CBWTF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONReports USD
#341 of 1,418 Healthcare companies by revenue67th-percentile growth
EA Score
75B+FH 81DQ —GM 64SS 64
v0.1 · 45/100 weight · provisional
↑ net margin, return on assets · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$111.7M
Rev growth YoY (TTM)
+11.8%
Net income (FY)
$29.9M
Employees
446
as of 2026-08-14
Market cap
$190.5M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$108.3M151.4M CAD2025
Net income$29.9M41.8M CAD2025
Operating income-$17.5M-24.4M CAD2025
Total assets$198.0M271.4M CAD2025
Liabilities$68.6M94.0M CAD2025
Equity$129.5M177.4M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Auxly Cannabis Group Inc.’s revenue?
Auxly Cannabis Group Inc. booked $108.3M in FY2025 revenue, growing 21% year over year — faster than most Healthcare companies we track, at a 27.6% net margin.
Peers · Healthcare
UroGen Pharma Ltd.55COptimizeRx Corp.72BCentury Therapeutics, Inc.48DTheravance Biopharma Inc75B+Zevra Therapeutics, Inc.70BZymeworks Inc.55CKey facts
CEOHugo Alves
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeOTC: CBWTF
Employees446
IPO date2017-04-07
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.